Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin Next Article
Apixaban superior to VKAs for major bleeding, stroke/STE and all-cause mortality »
« Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin Next Article
Apixaban superior to VKAs for major bleeding, stroke/STE and all-cause mortality »
Related Articles
January 20, 2022
People with HIV at higher risk of heart failure
June 1, 2022
First results of the POWER FAST III trial

September 7, 2020
Letter from the Editor
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy